Travere Therapeutics (TVTX) Stock
Specialized biotech focused on rare kidney disease treatments. Here's the price, business snapshot, and what's worth knowing about Travere Therapeutics in August 2026.
Travere Therapeutics (TVTX) is a biopharmaceutical company focused on treatments for rare kidney and other rare diseases, with particular emphasis on proteinuric kidney disorders. Investors should know Travere centres its strategy on a small portfolio of specialised programmes, with a lead candidate aimed at reducing proteinuria in conditions such as focal segmental glomerulosclerosis (FSGS) and IgA nephropathy. The company balances clinical development with efforts to commercialise therapies for niche patient populations; revenues and growth depend heavily on trial outcomes, regulatory decisions and uptake in specialist centres. As a mid-cap biotech (market cap roughly $2.48bn), the stock can be more volatile than large-cap pharmaceutical peers and sensitive to clinical newsflow and reimbursement dynamics. Potential upside comes from successful trial readouts and market adoption, while downside risks include clinical setbacks, regulatory delays and pricing pressure. This summary is for educational purposes only and is not personalised investment advice; consider consulting a financial adviser before investing.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts suggest buying Travere Therapeutics' stock with a target price of $39.37, indicating growth potential.
Financial Health
Travere Therapeutics is generating strong revenue and cash flow, with impressive profit margins.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Pipeline Catalysts Ahead
Clinical readouts and regulatory milestones can move the stock; these events offer potential upside but also carry clear binary risk.
Specialist Market Focus
Concentrating on rare kidney diseases may allow premium pricing and focused uptake in specialist centres, though patient‑population size limits scale.
Commercial & Reimbursement
Successful commercialisation depends on payer decisions and clinic adoption; reimbursement dynamics can materially affect revenue prospects.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
